Zhejiang Dayang Biology Technology Co.,Ltd.(003017.SZ)
No price history available.
Key financial summary
Financials in CNY| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | CNYm | 678 | 783 | 1,058 | 919 | 910 | 1,045 | N/A | N/A |
| Operating profit | CNYm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net profit | CNYm | 92 | 70 | 81 | 50 | 64 | 100 | N/A | N/A |
| EPS reported | CNY | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating cashflow per share | CNY | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Capex per share | CNY | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF per share | CNY | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Free cash flow | CNYm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt | CNYm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Book value equity | CNYm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Book value per share | CNY | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Number of shares | m | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| DPS (TTM paid) | CNY | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
Financial summary
Financials in CNY| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/B LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/S LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/FCF LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EV/EBITDA LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EV/Sales LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Earnings Yield LTM | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF Yield | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Quality | |||||||||
| ROE | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| ROIC | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating margin | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Gross margin | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF/Sales | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Growth and momentum | |||||||||
| EPS Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Sales Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net Income Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating Profit Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Dividend and capital structure | |||||||||
| Dividend Yield | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Dividend Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Payout Ratio | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF/Debt | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net Debt/EBITDA | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EBIT/Net interest | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt/market cap | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt/Equity | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Gross debt/equity | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
Company overview
Zhejiang Dayang Biology Technology Co.,Ltd. is a diversified enterprise specializing in the research, development, manufacturing, and global distribution of biological products, agricultural chemicals, and a broad spectrum of chemical compounds. Its extensive product portfolio includes a range of fundamental inorganic chemicals such as potassium carbonate (available in both general and food additive grades) and potassium bicarbonate (also offered as a food additive). They also supply ammonium chloride, catering to both agricultural and industrial needs. Beyond these, the company produces more specialized chemical derivatives, including 2-chloro-6-fluorobenzaldehyde, 2-chloro-6-fluorobenzyl chloride, and various anisole-based products. Furthermore, Zhejiang Dayang is a supplier of veterinary active pharmaceutical ingredients (APIs), exemplified by amprolium HCL, and manufactures veterinary drug premixes, such as enramycin premixes. Established in 1976, the company maintains its headquarters in Jiande, China.
Similar companies
- Wuxi Honghui New Materials Technology Co., Ltd.
- Daqing Huake Company Limited
- Ningxia Yinglite Chemicals Co., Ltd
- Jilin Province Xidian Pharmaceutical Sci-Tech Development Co.,Ltd
- Maoming Petro-Chemical Shihua Co., Ltd
- Shanxi Huayang New Material Co.,Ltd.
- PT Unggul Indah Cahaya Tbk
- Jiangsu Lanfeng Bio-chemical Co.,Ltd
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
Zhejiang Dayang Biology Technology Co.,Ltd. (003017.SZ)
No price history available.
Not enough data to calculate KvantraRank
Based on consensus from external analysts. Not Kvantra's opinion.
Zhejiang Dayang Biology Technology Co.,Ltd. is a diversified enterprise specializing in the research, development, manufacturing, and global distribution of biological products, agricultural chemicals, and a broad spectrum of chemical compounds. Its extensive product portfolio includes a range of fundamental inorganic chemicals such as potassium carbonate (available in both general and food additive grades) and potassium bicarbonate (also offered as a food additive). They also supply ammonium chloride, catering to both agricultural and industrial needs. Beyond these, the company produces more specialized chemical derivatives, including 2-chloro-6-fluorobenzaldehyde, 2-chloro-6-fluorobenzyl chloride, and various anisole-based products. Furthermore, Zhejiang Dayang is a supplier of veterinary active pharmaceutical ingredients (APIs), exemplified by amprolium HCL, and manufactures veterinary drug premixes, such as enramycin premixes. Established in 1976, the company maintains its headquarters in Jiande, China.
- Wuxi Honghui New Materials Technology Co., Ltd.
- Daqing Huake Company Limited
- Ningxia Yinglite Chemicals Co., Ltd
- Jilin Province Xidian Pharmaceutical Sci-Tech Development Co.,Ltd
- Maoming Petro-Chemical Shihua Co., Ltd
- Shanxi Huayang New Material Co.,Ltd.
- PT Unggul Indah Cahaya Tbk
- Jiangsu Lanfeng Bio-chemical Co.,Ltd